Aug 28, 2026 06:25AM
Aug 28, 2026 06:00AM
May 28, 2026 07:00AM
May 28, 2026 07:00AM
May 15, 2026 07:00AM
Apr 17, 2026 07:01AM
Apr 17, 2026 07:00AM BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
Apr 8, 2026 07:02AM
Apr 8, 2026 07:00AM
Apr 2, 2026 06:43AM
Apr 1, 2026 07:03AM
Apr 1, 2026 07:01AM
Apr 1, 2026 07:00AM
Apr 1, 2026 07:00AM BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
Mar 27, 2026 07:00AM
Mar 17, 2026 07:57AM
Mar 5, 2026 07:00AM
Mar 5, 2026 07:00AM
Feb 19, 2026 07:00AM
Feb 12, 2026 07:01AM
Feb 12, 2026 07:00AM BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting
Jan 20, 2026 07:01AM
Jan 20, 2026 07:00AM
Jan 12, 2026 07:00AM
Jan 7, 2026 07:00AM
Jan 7, 2026 07:00AM
Nov 12, 2025 07:00AM
Oct 17, 2025 06:48AM H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)
Oct 14, 2025 07:03AM
Oct 14, 2025 07:00AM
Sep 22, 2025 06:47AM
Sep 18, 2025 07:00AM
Sep 18, 2025 07:00AM
Sep 10, 2025 06:30AM
Sep 10, 2025 06:30AM BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
Sep 4, 2025 07:00AM
Aug 27, 2025 08:01AM
Aug 27, 2025 08:00AM
Aug 27, 2025 07:00AM
Aug 27, 2025 07:00AM
Aug 27, 2025 07:00AM
Aug 26, 2025 04:00PM BioXcel Therapeutics to announce phase 3 trial results for agitation treatment
Aug 26, 2025 04:00PM
Aug 19, 2025 07:00AM
Aug 19, 2025 07:00AM
Aug 18, 2025 07:00AM
Aug 18, 2025 07:00AM
Aug 18, 2025 06:48AM
Aug 15, 2025 09:36AM BioXcel Therapeutics receives preliminary FDA feedback ahead of meeting
Aug 13, 2025 07:00AM

329,907 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All